



Published in final edited form as:

J Mech Behav Biomed Mater. 2017 January ; 65: 295–305. doi:10.1016/j.jmbbm.2016.08.034.

The influence of pore size and stiffness on tenocyte bioactivity and transcriptomic stability in collagen-GAG scaffolds

William K. Grier¹, Ehiremen M. Iyoha¹, and Brendan A.C. Harley^{1,2,*}

¹Dept. of Chemical & Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801

²Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801

Abstract

Orthopedic injuries, particularly those involving tendons and ligaments, are some of the most commonly treated musculoskeletal ailments, but are associated with high costs and poor outcomes. A significant barrier in the design of biomaterials for tendon tissue engineering is the rapid de-differentiation observed for primary tenocytes once removed from the tendon body. Herein, we evaluate the use of an anisotropic collagen-glycosaminoglycan (CG) scaffold as a tendon regeneration platform. We report the effects of structural properties of the scaffold (pore size, collagen fiber crosslinking density) on resultant tenocyte bioactivity, viability, and gene expression. In doing so we address a standing hypothesis that scaffold anisotropy and strut flexural rigidity (stiffness) co-regulate long-term maintenance of a tenocyte phenotype. We report changes in equine tenocyte specific gene expression profiles and bioactivity across a homologous series of anisotropic collagen scaffolds with defined changes in pore size and crosslinking density. Anisotropic scaffolds with higher crosslinking densities and smaller pore sizes were more able to resist cell-mediated contraction forces, promote increased tenocyte metabolic activity, and maintain and increase expression of a tenogenic gene expression profiles. These results suggest that control over scaffold strut flexural rigidity via crosslinking and porosity provides an ideal framework to resolve structure-function maps relating the influence of scaffold anisotropy, stiffness, and nutrient biotransport on tenocyte-mediated scaffold remodeling and long-term phenotype maintenance.

Keywords

collagen; scaffold; pore size; crosslinking; tenocyte; bioactivity

Corresponding Author: B.A.C. Harley, Dept. of Chemical and Biomolecular Engineering, Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, 110 Roger Adams Laboratory, 600 S. Mathews Ave., Urbana, IL 61801, Phone: (217) 244-7112, Fax: (217) 333-5052, bharley@illinois.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Author contributions:

W.K.G. and B.A.C.H. designed the research; W.K.G. and E.M.I. performed the research; W.K.G., E.M.I., and B.A.C.H. analyzed the data; W.K.G. and B.A.C.H. wrote the manuscript.

Introduction

Geometrically and mechanically anisotropic tissues present unique challenges for the field of tissue engineering. The functional capacity of tendon derives from its extracellular matrix (ECM) composed of type I collagen arranged in highly aligned cross-linked fibrils (James et al., 2008; Liu et al., 2008; Towler and Gelberman, 2006). The cellular component of tendon is primarily composed of tendon fibroblasts, or tenocytes, distributed throughout a hierarchical organization of aligned type I collagen fibers (James et al., 2008; Liu et al., 2008). Tendon and ligament injuries plague individuals from all walks of life, from elite athletes to the elderly, with more than 32 million occurrences every year in the US alone (Breidenbach et al., 2013; James et al., 2008; Liu et al., 2008; Xu and Murrell, 2008). While small tendon injuries heal spontaneously via regeneration, larger defects undergo a repair-mediated process generating fibrocartilagenous scar tissue with inferior structural and biomechanical properties. The resulting misaligned ECM leads to losses in range of motion and strength along with high rates of injury recurrence (James et al., 2008; Liu et al., 2008; Xu and Murrell, 2008). Inadequate healing after surgical repair remains a primary clinical challenge. Because the musculoskeletal system depends on a balance of contributions from multiple tissues to maintain joint patency, ineffective tendon repair has both short-term (*i.e.* slowed rehabilitation) and long-term (*i.e.* chronic, degenerative joint pathologies) consequences (Butler et al., 2008; Liu et al., 2008). Due to an ageing US population with increasing rates of underlying chronic conditions (*i.e.* obesity, diabetes), injury volume and complexity are only expected to increase (Fox et al., 2011).

A primary challenge to improving tendon regeneration is poor understanding of how tenocytes respond to the dynamic structural microenvironment within tendon. Tendon fibroblasts, or tenocytes (TCs) are responsible for tendon homeostasis, remodeling, and repair. However, tenocytes exhibit rapid de-differentiation when cultured in 2D or within hydrogels (Clegg et al., 2007; Taylor et al., 2009). While tensile loading and aligned topographical cues on two-dimensional substrates can partially abrogate this effect (Caporali et al., 2009; Maeda et al., 2009; Paxton et al., 2011), 3D platforms for stable expansion of tenocytes represent an important advance for the field. A primary effort in the development of tissue engineering and regenerative medicine approaches for a range of tissues is therefore the design of an appropriate biomaterial platform. Often these approaches are inspired by the native extracellular matrix (ECM) in order to provide an environment to speed healing or regeneration (Spilker et al., 2001; Yannas, 2001; Yannas et al., 1989).

Collagen-glycosaminoglycan (CG) scaffolds have been used in a wide variety of *in vivo* applications for skin, peripheral nerve, and cartilage tissue engineering as well as 3D environments for *in vitro* studies of cell-matrix interactions (cell, migration and contraction) behavior (Farrell et al., 2006; Harley et al., 2007a; Harley et al., 2008; Harley et al., 2004; O'Brien et al., 2005; Schulz Torres et al., 2000; Yannas et al., 1989). The vast majority of past efforts using CG scaffolds have focused primarily on the regeneration of soft tissues. However, those scaffold variants were unsuitable for tendon repair applications due to their inability to withstand TC-mediated contraction (Caliari and Harley, 2011; Schulz Torres et al., 2000) leading to rapid tenocyte de-differentiation. We have recently developed a

fabrication method to produce anisotropic CG scaffolds composed of an aligned ellipsoidal pore structure (Caliari and Harley, 2011). This anisotropic scaffold geometry promotes preferential tenocyte alignment along the long axis of the ellipsoidal pores. Interestingly, increasing the scaffold relative density while maintaining the aligned pore geometry was shown to reduce TC-mediated scaffold contraction, maintain an aligned morphology, and reduce TC de-differentiation (Caliari and Harley, 2011; Caliari et al., 2011; Caliari et al., 2012). The potential to tailor scaffold anisotropy and its resistance to adverse (contraction-based) remodeling events offers an exciting platform to control long-term maintenance of tenocyte bioactivity. Here, we look at two different means to alter the local scaffold environment experienced by individual tenocytes: *pore size* and *crosslinking density*. For a low-density open-cell foam such as the CG scaffold, changing scaffold pore size does not affect macro-scale mechanical properties such as scaffold elastic modulus (Gibson et al., 2010; Harley et al., 2007c); however, changing the pore size for a series of scaffolds with constant relative density does alter the length and thickness (hence flexural rigidity) of individual struts which define the pore structure of the scaffold (Harley et al., 2007a). Alternatively, increasing scaffold crosslinking density via either dehydrothermal (DHT) (Gibson et al., 2010; Harley et al., 2007c; Olde Damink et al., 1996; Schulz Torres et al., 2000) or chemical (1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride, EDC; N-hydroxysulfosuccinimide, NHS) (Olde Damink et al., 1996) means can increase scaffold and individual strut stiffness independent of pore size. Both modifications alter the local strut properties but via different means, opening the door to questions exploring how strut stiffness versus pore size affects TC-mediated contraction and resultant maintenance of TC-phenotype.

The work presented here seeks to describe the relationship between scaffold pore size and crosslinking with scaffold mechanical properties and its ability to resist TC-mediated contraction. We hypothesized that scaffold's ability to resist TC-mediated contraction would increase with increasing crosslinking density and decreasing pore size. Moreover, more mechanically robust scaffolds with smaller pore sizes and higher crosslinking densities were hypothesized to be more supportive of the maintenance of a tendon-like phenotype through the resistance to TC-mediated contraction and preservation of a permeable open-cell pore structure that allows for efficient nutrient transport and cell spreading. While our group and others have investigated the impact of initial scaffold pore size and crosslinking on cell attachment and tenocyte contraction (Caliari and Harley, 2011; Caliari et al., 2012; Schulz Torres et al., 2000), this previous work only considered cell-mediated contraction (but not genomic stability) as an endpoint (Schulz Torres et al., 2000) or did not fully examine the combinatorial effect of EDC crosslinking density and scaffold pore size on TC-mediated contraction and subsequent bioactivity (Caliari and Harley, 2011; Caliari et al., 2012). As a result, in this manuscript we explored the combined effect of scaffold crosslinking density and pore size on tenocyte-mediated contraction and genomic stability, using strut flexural rigidity as a means to consider the results.

Materials & Methods

Preparation of CG suspension

Type I microfibrillar collagen from bovine tendon (Sigma-Aldrich, St. Louis, MO) and chondroitin-4,6-sulfate from shark cartilage (Sigma-Aldrich, St. Louis, MO) were homogenized in 0.05M acetic acid. The concentration of the collagen suspension made was 1.0%, and the ratio of the collagen to glycosaminoglycan was kept at 11.25:1 (Caliari and Harley, 2011; O'Brien et al., 2004; Yannas et al., 1989).

Aligned CG scaffold fabrication

The scaffolds were fabricated through directional solidification as previously described (Caliari and Harley, 2011). Degassed CG suspension was pipetted into a polytetrafluoroethylene (PTFE)-copper mold (8mm diameter, 15mm deep), and placed on a pre-cooled freeze-dryer shelf (VirTis, Gardner, NY). The mismatch in thermal conductivity between the PTFE body and copper base of the mold promotes unidirectional heat transfer through the more conductive copper, resulting in anisotropic ice crystal formation when cooled (Caliari and Harley, 2011). In order to control pore size, the CG suspension was frozen at three different temperatures (T_f): -10°C , -40°C , and -60°C . These freezing temperatures have been previously shown to produce scaffolds with aligned pore geometries of 243, 152, and 55 μm diameters respectively (Caliari and Harley, 2011). The CG suspensions were frozen for 2h, and then sublimated at 0°C and 200mTorr to remove the ice crystals, resulting in a dry porous scaffold.

Aligned CG scaffold crosslinking

Following lyophilization, the scaffolds were DHT crosslinked in a vacuum oven (Welch, Niles, IL) (105°C , <25 torr) for 24 h and then stored in a desiccator until use. Before use, scaffolds were immersed in 200-proof ethanol for 6 hours, followed by washing with phosphate-buffered saline (PBS) overnight. Solutions of 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (Sigma-Aldrich, St. Louis, MO) and N-hydroxysulfosuccinimide (Sigma-Aldrich) were used to further crosslink each of the three scaffolds groups at three different molar ratios: 1:1:5 (low), 5:2:5 (medium), and 5:2:1 (high) EDC:NHS:COOH that correspond with increasing collagen strut and overall scaffold stiffness (Harley et al., 2007c; Olde Damink et al., 1996). While characterization of the pore size (Caliari and Harley, 2011) and relative changes in modulus ($E_{5:2:1} \sim 3.6$ -fold greater than $E_{1:1:5}$) (Harley et al., 2007b) and swelling ratio (EDC $_{1:1:5} \sim 1.6$ -fold greater swelling than EDC $_{5:2:5}$) (Vickers et al., 2010) with crosslinking have been previously published, a summary of properties for the library of scaffolds tested here is provided in Table 1.

Equine tenocyte isolation and culture

Equine tenocytes were isolated as previously described (Caliari and Harley, 2011) from horses aged 2–3 years euthanized for reasons not related to tendinopathy and in a manner consistent with protocols approved by the University of Illinois IACUC. Digital flexor tendons were extracted, diced, and incubated in trypsin–ethylenediaminetetraacetic acid (Invitrogen, Carlsbad, CA) then 0.15% collagenase II (Worthington, Lakewood, NJ)

overnight at 37°C under constant shaking. Digest solution was filtered (40 µm pore size) to isolate tenocytes (Kapoor et al., 2010). All cell concentrations were determined using a Bright-Line hemocytometer (Sigma Aldrich). Tenocytes were plated at a density of 1×10^4 cells/cm², and cultured in high glucose Dulbecco's modified Eagle's medium (DMEM, Fisher, Pittsburgh, PA) with 1% L-glutamine (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, Invitrogen, Carlsbad, CA), 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA), 1% amphotericin-B (MP Biomedical, Solon, OH), and 25 µg/mL ascorbic acid (Wako, Richmond, VA) (Caliari and Harley, 2011). The tenocytes were cultured at 37°C and 5% CO₂, and were fed every 3 days. Cells were used at passage 3.

Scaffold seeding

Each cylindrical CG scaffold (8mm diameter, 15mm length) was cut into ~5mm long plugs (8mm dia.), and placed in ultra-low attachment 6-well plates (Corning Life Sciences, Lowell, MA). Confluent tenocytes were trypsinized and resuspended at a concentration of 5×10^5 cells/20 µL media. Scaffolds were seeded with tenocytes using a previously validated static seeding method (Caliari and Harley, 2011; O'Brien et al., 2005) with 10 µL of cell suspension (2.5×10^5 cells) pipetted directly onto each scaffold. The scaffolds were then incubated at 37°C for 15 minutes, turned over, and seeded with an additional 10 µL of cell suspension for a total of 5×10^5 cells seeded per scaffold. The cell-seeded scaffolds were then incubated at 37°C with 5% CO₂ and fed complete DMEM every 3 days (Caliari and Harley, 2011).

Quantification of cell metabolic activity

The mitochondrial metabolic activity of the tenocytes within each scaffold was determined through the use of non-destructive AlamarBlue® assay as previously described (Caliari and Harley, 2011). Healthy, viable cells continuously convert the active ingredient in AlamarBlue® (resazurin) to a fluorescent byproduct (resorufin), allowing comparison of the gross metabolic activity of each cell-seeded construct. Cell-seeded scaffolds were incubated at 37°C in AlamarBlue (Invitrogen, Carlsbad, CA) solution with gentle shaking for 2 h (Tierney et al., 2009). Resorufin fluorescence was measured (excitation: 540 nm, emission: 590 nm) via a fluorescent spectrophotometer (Tecan, Switzerland). Relative cell metabolic activity was determined from a standard curve generated from known cell numbers prior to seeding the scaffolds and reported as a percentage of the total number of seeded cells.

Measurement of cell-mediated scaffold contraction

At days 1, 4, 7, and 14, the diameter of each scaffold disk was measured using a standard drafting template. The measurements were then normalized against the diameter of each scaffold at day 0 to determine cell-mediated contraction of each scaffold disk (Caliari et al., 2012; Spilker et al., 2001).

Quantification of cell number

The total number of cells on each scaffold was assayed via DNA quantification (Caliari and Harley, 2011; Kim et al., 1988). Scaffolds were rinsed in PBS and placed in a papain solution (Sigma-Aldrich, St. Louis, MO) (60°C, 24 hours) to digest the scaffolds and lyse

the cells. Hoechst 33258 dye (Invitrogen, Carlsbad, CA) was used to fluorescently label double-stranded DNA (Kim et al., 1988). Fluorescence was read (excitation: 360nm; emission: 465nm) via a fluorescent spectrophotometer (Tecan, Switzerland). The number of cells within the scaffolds after culture was normalized against the scaffold with the largest crosslinking density (5:2:1) and largest pore size ($-10^{\circ}\text{C } T_f$) in order to serve as a comparison to previous work (Caliari and Harley, 2011).

RNA isolation and real-time PCR

RNA from the tenocytes in the scaffolds was extracted at days 1, 4, 7, and 14, using an RNeasy Plant Mini kit (Qiagen, Valencia, CA) and then was reverse transcribed to cDNA in a Bio-Rad S1000 thermal cycler using the QuantiTect Reverse Transcription kit (Qiagen, Valencia, CA) as previously described (Caliari and Harley, 2011). Real-time PCR reactions were carried out in triplicate, using 10ng of cDNA and QuantiTect SYBR Green PCR kit (Qiagen, Valencia, CA) in a 7900HT Fast Real-Time PCR system (Carlsbad, CA). The primers used were consistent with previous studies (Table 2; collagen type I alpha 2; collagen type III alpha 1; cartilage oligomeric matrix protein; decorin; scleraxis; tenascin-c, C; matrix metalloproteinases 1, 3, and 13; glyceraldehyde 3-phosphate dehydrogenase, housekeeping) (Caliari and Harley, 2011; Caliari et al., 2012), and were synthesized by Integrated DNA Technologies (Coralville, IA). Results were generated using the C_t method and all results were expressed as fold changes normalized to the expression levels of cells on the $-10^{\circ}\text{C}/5:2:1$ scaffold group at day 1 for comparison to previous studies (Caliari and Harley, 2013; Caliari and Harley, 2011; Caliari et al., 2011; Caliari et al., 2012). The expression levels of the MMP genes are shown relative to the normalized scaffold contraction for each group at each time point in order to better elucidate the interplay of cell-mediated contraction forces and cell-mediated remodeling (Clegg et al., 2007; Gotoh et al., 1997; Jones et al., 2006; Lo et al., 2004)

Statistical Analysis

One-way analysis of variance (ANOVA) was performed on all data sets within each group to examine differences with time, while two-way ANOVAs (independent factors: crosslinking density, T_f) were applied to data sets for each time point. For scaffold contraction, significant changes from the day 0 time point were determined by Dunnett's post-hoc test. Statistical significance for all other measurements was determined by Tukey-HSD post-hoc tests. Significance was set at $p < 0.05$. Cell metabolic activity ($n=6$), scaffold diameter ($n=6$), and gene expression ($n=3$) were analyzed at each time point. For MMP gene expression relative to normalized scaffold diameter, linear or exponential regression models were used to fit the data and corresponding R^2 values ($n = 27$) were reported. Error was reported in figures as the standard error of the mean unless otherwise noted.

Results

Tenocyte viability in CG scaffolds

Tenocytes remained viable in all scaffold variants across the fourteen day experiment. While the metabolic activity of the tenocyte-seeded scaffolds was consistent for all scaffold groups at day 1 after seeding, by day 14 significant expansion in overall metabolic activity and cell

number was observed. Here, cell number and construct metabolic activity increased significantly ($p < 0.01$) with crosslinking density, with the largest increases in cell number and metabolic activity seen for the most strongly crosslinked (EDC:NHS:COOH 5:2:1) variants (Figure 1A, 1B). A significant effect of both crosslinking density ($p < 0.001$) and scaffold pore size (T_f , $p < 0.001$) was observed on tenocyte mediated scaffold contraction (Figure 1C). Scaffolds crosslinked at the lightest (1:1:5) density started showing signs of contraction as early as day 1, then showed significantly ($p < 0.01$) greater contraction (smaller normalized diameter) than scaffolds crosslinked at higher densities on all following days. Scaffolds crosslinked at a middle (5:2:5) density began to show signs on contraction by day 4, and on all following days were significantly more contracted than the scaffolds crosslinked at the highest (5:2:1) density, which exhibited little-to-no contraction throughout the 14-day experiment. For crosslinking densities that yielded significant contraction (1:1:5, 5:2:5), there was also a significant ($p < 0.01$) effect of scaffold pore size on contraction. Scaffolds with larger pore sizes (higher T_f) showed greater contraction when compared to scaffolds with the same crosslinking density but smaller pore sizes.

Tenocyte gene expression within CG scaffolds

We subsequently examined the gene expression profiles of the cells remaining in each construct after 14 days in culture. Three distinct sub-sets of genes were examined: structural proteins associated with tendon ECM (*COL1A2*, *COL3A1*, *COMP*, *DCN*; Figure 2); genes associated with tendon phenotype (*SCX*, *TNC*; Figure 3); and genes associated with matrix remodeling (*MMP1*, *MMP3*, *MMP13*; Figure 4).

Structural protein gene expression

Gene expression levels of *COL1A1*, *COL3A3*, *COMP*, and *DNC* showed some global changes in expression for earlier time points (days 1, 4, and 7; Supplementary Figures 1, 2). By day 4, the scaffolds least resistant to contraction (1:1:5 crosslinking density) showed significant increases in *COL3A1*, *COMP*, and *DCN*, while scaffolds moderately able to resist contraction (5:2:5 crosslinking density) showed significantly higher expression of all four structural protein markers and scaffolds most resistant to contraction (5:2:1 crosslinking density) only showed increased expression of *DCN*. More interestingly, we examined changes in structural genes at day 14, at which point significant cell-mediated contraction had occurred (Figure 2). Notably, scaffolds most resistant to contraction (5:2:1 crosslinking density; -40°C and -60°C T_f) showed significantly higher expression of *COL1A2* compared to scaffolds with lower crosslinking densities and the same T_f (Figure 2). Further, while not always significant an overall change in expression profiles for all genes were observed, with crosslinking groups less resistant to contraction (1:1:5, 5:2:5) showing decreases in expression with decreasing pore size while the crosslinking groups most resistant to contraction (5:2:1) showing increasing in expression with decreasing pore size. Finally, while there were no significant differences in expression of *DCN*, the scaffold with the smallest pores most resistant to contraction (-60°C T_f ; 5:2:1 crosslinking) showed significantly higher expression of *COMP* than all other scaffold groups at day 14 (Figure 2).

Tendon phenotype gene expression

Expression of the transcription factor *SCX* increased initially in all scaffold variants (through day 4). However, significant cell-mediated contraction began to affect the expression profile for subsequent days for the scaffold groups least resistant to contraction (1:1:5 and 5:2:5 crosslinking density) while the scaffold group resistant to contraction (5:2:1 crosslinking density) maintained the elevated *SCX* expression through days 14 (Supplementary Figure 3). Comparing between scaffold pore size and crosslinking at day 14, we observed the scaffold variant most resistant to contraction (5:2:1 crosslinking density, -60°C T_f) showed significantly higher *SCX* expression than all other groups. Further scaffolds with reduced resistance to contraction (1:1:5 crosslinking density, -40°C T_f) showed significantly lower expression of *SCX* than all other groups (Figure 3). *TNC* expression followed a similar trend to *SCX*, with all groups showing increased expression though day 7 (Supplementary Figure 3). While not significant by day 14, an increasing trend in *TNC* expression was observed for scaffolds most resistant to contraction (5:2:1 crosslinking density; -40 and -60°C T_f).

MMP gene Expression

All three MMP genes examined (*MMP1*, *MMP3*, and *MMP13*) showed similar trends regarding expression between groups and over time (Supplementary Figure 4). In general, MMP expression levels increased with time point and were significantly higher in the scaffolds least resistant to contraction (warmer T_f , lower crosslinking densities). More interestingly, we subsequently examined MMP expression profiles against the normalized (versus starting diameter) diameter of each scaffold, collapsing the effect of time, pore size, and crosslinking density onto a single plot (Figure 4). With the exception of day 1 at which point minimal contraction had taken place ($R^2 = 0.25$), we observed very strong correlation between increasing MMP expression profiles and increased scaffold contraction, with $R^2 = 0.84$ for day 14 results. Interestingly, *MMP1* and *MMP3* showed effectively linear increases in expression with scaffold crosslinking and time, while *MMP13* showed an exponential increase in expression with time. Scaffolds least resistant to contraction (1:1:5 density, -10°C T_f) showed more than 600 fold increase in *MMP13* over the course of 14 days (Figure 4C).

Discussion

Biomaterial scaffold mechanical properties at both the macro and micro-scales have been widely reported to influence cellular behaviors such as adhesion, migration, proliferation, and differentiation (Engler et al., 2004; Freyman et al., 2001; Grinnell et al., 2003; Pelham and Wang, 1997; Peyton and Putnam, 2005; Yeung et al., 2005; Zaman et al., 2006). The motivation for this work is the significant de-differentiation often observed with tenocytes when culture in vitro as well as the observation that structural alignment in two-dimensions and application of tensile strain may reduce this de-differentiation (Taylor et al., 2009). Future tendon tissue engineering efforts require the expansion of primary tenocytes in order to address large injuries, necessitating approaches that use three-dimensional biomaterial constructs for cell culture and eventual in vivo implantation. If a microstructurally-aligned material is unable to maintain a high degree of anisotropy due to contractile forces, the

microstructural cues that guide cell-fate decisions will be significantly altered as the cells remodel the local microenvironment.

Here we describe the production and analysis of a series of anisotropic CG scaffolds fabricated at different T_f and a range of crosslinking densities for the in vitro culture of primary equine tenocytes. Our group recently described an approach where the relative density of a series of CG scaffolds was varied in order to prevent TC-mediated contraction, resulting in reduced scaffold contraction, maintenance of the aligned structural cues provided by the scaffold and resultant increased maintenance of TC-associated gene expression profiles for cells within the scaffold (Caliari et al., 2012). However, changes in the relative density of the scaffold result in changes in scaffold pore size as well as in the mechanical properties of the scaffold at the scale of the overall construct and at the level of an individual cell within the scaffold. This observation therefore motivated our effort here to generate a wider library of CG scaffolds to more specifically examine the effect of scaffold architecture on resultant TC-mediated contraction and phenotypic stability.

Low-density open-cell foams such as the CG scaffold demonstrate a unique set of structure-mechanic relationships (Gibson et al., 2010). For these materials it is essential to consider the mechanical property at the scale of the overall construct (bulk properties) as well as at the level of the individual fibers (termed struts) that make up the scaffold architecture and to which individual cells attach. The bulk mechanical properties of the scaffold depend critically on the crosslinking density and relative density ($1 - \text{porosity}$), not pore size, of the scaffold. For example, the elastic modulus of the bulk scaffold (E^*) depends on the crosslinking density of the collagen (defining E_s , the modulus of the individual strut) along with the relative density (ρ^*/ρ_s) of the scaffold: $E^* \sim E_s (\rho^*/\rho_s)^2$ (Harley et al., 2007c). However, modulus is insensitive to scaffold pore size (Gibson and Ashby, 1997; Harley et al., 2007c). However, cell-mediated contraction is mediated not by the bulk elastic properties, but rather the mechanical properties of the individual struts to which they attach. Previous studies have shown that contractile cells possess the ability to generate sufficient contractile forces to buckle individual struts and deform the local pore structure around them (Freyman et al., 2001). These local contractions, when compounded throughout the entire scaffold result in a macroscopic deformation of the overall scaffold. Further, the magnitude of contractile forces generated by individual cells can be estimated via the flexural rigidity of the strut, which depends on crosslinking density (E_s) and also the length and thickness of the strut (Harley et al., 2007a). Here, increasing the pore size for a series of scaffolds with a set relative density increases the length of individual struts (Harley et al., 2007c). Therefore, selective modification to both scaffold crosslinking and pore size provides a wider platform to consider the influence of local strut mechanical properties, resistance to TC-mediated contraction, and subsequent maintenance of tenogenic gene expression profiles within the scaffold.

For this project we employed a previously defined set of scaffold fabrication techniques, altering the freezing temperature during lyophilization to generate a series of anisotropic scaffolds within decreasing pore size (-10°C , -40°C , -60°C ; 243, 152, and 55 μm pore size) (Caliari and Harley, 2011). We subsequently employed a series of three discrete carbodiimide crosslinking densities (1:1:5, 5:2:5, 5:2:1) that span a 3.6-fold increase in

stiffness (Harley et al., 2007c). TC-mediated contraction, metabolic activity and cell number, and resultant changes in gene expression profiles for a diverse set of tendon-associated structural proteins, tenocyte markers, and matrix-remodeling genes were then traced across the full set of 9 experimental scaffold groups. Here, we observed scaffold pore size and crosslinking density were able to elicit differential responses during long-term cell culture.

In general, an increase in the number and metabolic activity of primary equine tenocytes was observed with culture time. However, we noted a significant effect of both crosslinking density and scaffold pore size on cell-mediated contraction of the scaffolds (Figure 1A). Not surprisingly, increasing scaffold crosslinking density resulted in reduced cell-mediated contraction; however, we also noted a significant effect of pore size on contraction, with scaffolds containing smaller pores more able to resist cellular contractile forces over time (Figure 1C). The loss of structural stability via contraction has a significant negative effect on cell metabolic activity due with time, likely due to reduced biotransport as a result of the more contracted scaffold structure. Applied compressive loading has previously been shown to alter bulk scaffold permeability (O'Brien et al., 2007; Weisgerber et al., 2013), suggesting the need for improved technologies to locally monitor scaffold permeability as a result of localized cell-contraction. So while we observed a significant reduction in metabolic activity and cell number after 14 days of culture in scaffolds that exhibited significant contraction (Figure 1A, 1B), it was important to establish the effect of this contraction on the phenotype of the resultant cells.

We subsequently examined the effects of cell-mediated contraction on the maintenance of a healthy tendon-like phenotype via transcript levels of ECM proteins associated with native tendon (*COL1A2*, *COL3A1*, *COMP*, *DCN*) (Lui et al., 2011) as well as transcription factors and matricellular markers of tenocytes (*SCX*, *TNC*) (Blitz et al., 2009; Doroski et al., 2010; Pryce et al., 2009; Schweitzer et al., 2010) (Figures 2–3). Lastly, we also examined a series of matrix metalloproteinases (*MMP1*, *MMP3*, *MMP13*) important for cell migration, wound healing, and matrix remodeling, but also whose reduced expression levels are indicative of healthy tendon (Clegg et al., 2007; Gotoh et al., 1997; Jones et al., 2006). Transcript levels at each time point were normalized against expression levels of tenocytes in scaffolds with a -10°C T_f and 5:2:1 crosslinking density to compare to previous studies investigating the influence of the CG scaffold microenvironment on the transcriptomic stability of tenocytes (Caliari and Harley, 2013; Caliari and Harley, 2011; Caliari et al., 2012). Importantly, by day 14, *COL1A2*, *COL3A1*, *COMP*, and *DCN* all showed decreased expression in scaffolds with reduced crosslinking 1:1:5 and 5:2:5 scaffolds and with the largest pore size (least resistant to contraction). Expression levels were increased in scaffolds most resistant to contraction ($T_f -60$; 5:2:1 crosslinking density). Expression of *SCX* was significantly higher in scaffolds most resistant to contraction ($T_f -60$; 5:2:1 crosslinking density) while *TNC* expression following a similar, but not significant, trend. Further, heightened *MMP1*, *MMP3*, and *MMP13* expression all followed nearly identical and dramatic trends. Most interestingly, plotting the results not as a function of scaffold pore size or crosslinking density, but rather versus overall resistance to TC-mediated contraction, these data collapse onto clear trends of reduced TC-associated markers with increasing cell-mediated contraction (Figure 4).

While our earlier results suggested reduced TC-associated markers with increasing scaffold contraction as a result in changes in overall scaffold relative density (Caliari et al., 2012), changes in relative density masked our ability to determine whether the stiffness of the scaffold strut versus the flexural rigidity of the strut was the primary design consideration that could be used in subsequent biomaterial variants. Here, by selectively modifying scaffold pore size and crosslinking density, we are able to independently tune strut length versus strut stiffness. Interestingly, we found that the overall ability to resist contraction was the best predictor of maintenance of tenocyte-associated gene expression profiles. However, examining the effect of pore size versus crosslinking in more detail, we note that crosslinking density provides a primary means to resist TC-mediated contraction. For lower crosslinking densities (1:1:5, 5:2:5) where significant contraction was observed, the poorest response was seen in the smallest pore size variants, likely due to the significant contraction not only destroying the aligned structure signals provided by the pore, but also significantly reducing biotransport. However, in the highest crosslinking density (5:2:1) where limited contraction was observed, the scaffold with the smallest pore size more resistant to contraction demonstrated the highest level of TC-associated genes. Together, these results suggest that while scaffold ability to resist TC-mediated contraction forces play a significant role in regulating tenocyte gene expression, increasingly scaffold crosslinking, not necessarily changes in pore size, provide the primary means to optimize culture conditions for expansion and maintenance of primary tenocytes. While future investigations will be required to further optimize the three-dimensional scaffold most appropriate for long-term tenocyte culture, findings here provide critical insight as to the use of crosslinking versus structural changes in the scaffold to accomplish this goal.

Conclusions

This work describes the evaluation of the ability for a series of anisotropic CG scaffolds to promote the expansion of primary tenocytes in vitro. In general, equine tenocytes showed increased proliferation and metabolic activity as well as less cell-mediated contraction in scaffolds with higher crosslinking densities and smaller pore sizes. Gene expression analysis showed scaffolds most resistant of cell-mediated contraction were able to maintain a tendon-like-phenotype over the course of the experiment. Importantly, the high expression levels of MMPs 1, 3, and 13 in scaffolds that showed more contraction indicate a high degree of scaffold remodeling and loss of tendon-like phenotype. This suggests that the structural stability of biomaterials for tissue engineering applications is of particular importance when considering clinical translation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to acknowledge Dr. Allison Stewart (Veterinary Sciences, UIUC) for providing equine tendon cells and the IGB Core Facilities for the use of their real-time PCR system. Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Numbers R03 AR062811 and R21 AR063331. We are grateful for funding provided by the Chemistry–Biology Interface Training Program NIH NIGMS T32GM070421 (WKG).

EMI was funded through a Research Experience for Undergraduates program within the National Science Foundation (NSF) Science and Technology Center Emergent Behavior of Integrated Cellular Systems (EBICS) Grant CBET-0939511. Additional support was provided by the Chemical and Biomolecular Engineering Dept. and the Carl R. Woese Institute for Genomic Biology (BACH) at the University of Illinois at Urbana-Champaign. This research was carried out in part in the Frederick Seitz Materials Research Laboratory Central Facilities, University of Illinois, which are partially supported by the U.S. Department of Energy under grants DE-FG02-07ER46453 and DE-FG02-07ER46471.

Funding. This work was supported by the National Institutes of Health (R03 AR062811 and R21 AR063331 to BACH; T32GM070421 to WKG) and the National Science Foundation (REU to EMI under CBET-0939511).

References

- Blitz E, Viukov S, Sharir A, Shwartz Y, Galloway JL, Pryce BA, Johnson RL, Tabin CJ, Schweitzer R, Zelzer E. Bone ridge patterning during musculoskeletal assembly is mediated through SCX regulation of Bmp4 at the tendon-skeleton junction. *Dev Cell.* 2009; 17:861–873. [PubMed: 20059955]
- Breidenbach AP, Gilday SD, Lalley AL, Dymont NA, Gooch C, Shearn JT, Butler DL. Functional tissue engineering of tendon: Establishing biological success criteria for improving tendon repair. *Journal of biomechanics.* 2013
- Butler DL, Juncosa-Melvin N, Boivin GP, Galloway MT, Shearn JT, Gooch C, Awad H. Functional tissue engineering for tendon repair: A multidisciplinary strategy using mesenchymal stem cells, bioscaffolds, and mechanical stimulation. *J Orthop Res.* 2008; 26:1–9. [PubMed: 17676628]
- Caliari SR, Harley BA. Composite Growth Factor Supplementation Strategies to Enhance Tenocyte Bioactivity in Aligned Collagen-GAG Scaffolds. *Tissue Eng Part A.* 2013
- Caliari SR, Harley BAC. The effect of anisotropic collagen-GAG scaffolds and growth factor supplementation on tendon cell recruitment, alignment, and metabolic activity. *Biomaterials.* 2011; 32:5330–5340. [PubMed: 21550653]
- Caliari SR, Ramirez MA, Harley BAC. The development of collagen-GAG scaffold-membrane composites for tendon tissue engineering. *Biomaterials.* 2011; 32:8990–8998. [PubMed: 21880362]
- Caliari SR, Weisgerber DW, Ramirez MA, Kelkhoff DO, Harley BAC. The influence of collagen-glycosaminoglycan scaffold relative density and microstructural anisotropy on tenocyte bioactivity and transcriptomic stability. *Journal of the Mechanical Behavior of Biomedical Materials.* 2012; 11:27–40. [PubMed: 22658152]
- Caporali E, Kapoor A, Kenis PA, Stewart MC. TGF- β and microtopographical cues promote expression of tenogenic marker genes and tenocyte alignment., *Proceedings of the 36th. Annual Conference of the Veterinary Orthopedic Society.* 2009
- Clegg PD, Strassburg S, Smith RK. Cell phenotypic variation in normal and damaged tendons. *International Journal of Experimental Pathology.* 2007; 88:227–235. [PubMed: 17696903]
- Doroski DM, Levenston ME, Temenoff JS. Cyclic tensile culture promotes fibroblastic differentiation of marrow stromal cells encapsulated in poly(ethylene glycol)-based hydrogels. *Tissue Eng Part A.* 2010; 16:3457–3466. [PubMed: 20666585]
- Engler A, Bacakova L, Newman C, Hategan A, Griffin M, Discher D. Substrate compliance versus ligand density in cell on gel responses. *Biophys J.* 2004; 86:617–628. [PubMed: 14695306]
- Farrell E, O'Brien FJ, Doyle P, Fischer J, Yannas I, Harley BA, O'Connell B, Prendergast PJ, Campbell VA. A collagen-glycosaminoglycan scaffold supports adult rat mesenchymal stem cell differentiation along osteogenic and chondrogenic routes. *Tissue engineering.* 2006; 12:459–468. [PubMed: 16579679]
- Fox AJ, Bedi A, Deng XH, Ying L, Harris PE, Warren RF, Rodeo SA. Diabetes mellitus alters the mechanical properties of the native tendon in an experimental rat model. *J Orthop Res.* 2011; 29:880–885. [PubMed: 21246619]
- Freyman TM, Yannas IV, Yokoo R, Gibson LJ. Fibroblast contraction of a collagen-GAG matrix. *Biomaterials.* 2001; 22:2883–2891. [PubMed: 11561894]
- Garvican ER, Vaughan-Thomas A, Redmond C, Clegg PD. Chondrocytes harvested from osteochondritis dissecans cartilage are able to undergo limited in vitro chondrogenesis despite

- having perturbations of cell phenotype in vivo. *Journal of Orthopaedic Research*. 2008; 26:1133–1140. [PubMed: 18327793]
- Gibson, LJ.; Ashby, MF. *Cellular solids: structure and properties*. 2nd. Cambridge University Press; Cambridge, U.K: 1997.
- Gibson, LJ.; Ashby, MF.; Harley, BA. *Cellular materials in nature and medicine*. Cambridge University Press; Cambridge; New York: 2010.
- Gotoh M, Hamada K, Yamakawa H, Tomonaga A, Inoue A, Fukuda H. Significance of granulation tissue in torn supraspinatus insertions: An immunohistochemical study with antibodies against interleukin-1 β , cathepsin D, and matrix metalloproteinase-1. *Journal of Orthopaedic Research*. 1997; 15:33–39. [PubMed: 9066524]
- Grinnell F, Ho CH, Tamariz E, Lee DJ, Skuta G. Dendritic fibroblasts in three-dimensional collagen matrices. *Mol Biol Cell*. 2003; 14:384–395. [PubMed: 12589041]
- Harley BA, Freyman TM, Wong MQ, Gibson LJ. A new technique for calculating individual dermal fibroblast contractile forces generated within collagen-GAG scaffolds. *Biophys J*. 2007a; 93:2911–2922. [PubMed: 17586570]
- Harley BA, Kim HD, Zaman MH, Yannas IV, Lauffenburger DA, Gibson LJ. Microarchitecture of three-dimensional scaffolds influences cell migration behavior via junction interactions. *Biophys J*. 2008; 95:4013–4024. [PubMed: 18621811]
- Harley BA, Leung JH, Silva EC, Gibson LJ. Mechanical characterization of collagen-glycosaminoglycan scaffolds. *Acta Biomater*. 2007b; 3:463–474. [PubMed: 17349829]
- Harley BA, Leung JH, Silva ECCM, Gibson LJ. Mechanical characterization of collagen-glycosaminoglycan scaffolds. *Acta Biomaterialia*. 2007c; 3:463–474. [PubMed: 17349829]
- Harley BA, Spilker MH, Wu JW, Asano K, Hsu HP, Spector M, Yannas IV. Optimal degradation rate for collagen chambers used for regeneration of peripheral nerves over long gaps. *Cells Tissues Organs*. 2004; 176
- James R, Kesturu G, Balian G, Chhabra AB. Tendon: biology, biomechanics, repair, growth factors, and evolving treatment options. *J Hand Surg Am*. 2008; 33:102–112. [PubMed: 18261674]
- Jones GC, Corps AN, Pennington CJ, Clark IM, Edwards DR, Bradley MM, Hazleman BL, Riley GP. Expression profiling of metalloproteinases and tissue inhibitors of metalloproteinases in normal and degenerate human achilles tendon. *Arthritis & Rheumatism*. 2006; 54:832–842. [PubMed: 16508964]
- Kapoor A, Caporali EHG, Kenis PJA, Stewart MC. Microtopographically patterned surfaces promote the alignment of tenocytes and extracellular collagen. *Acta Biomaterialia*. 2010; 6:2580–2589. [PubMed: 20045087]
- Kim YJ, Sah RLY, Doong JYH, Grodzinsky AJ. Fluorometric assay of DNA in cartilage explants using Hoechst 33258. *Analytical Biochemistry*. 1988; 174:168–176. [PubMed: 2464289]
- Liu Y, Ramanath HS, Wang DA. Tendon tissue engineering using scaffold enhancing strategies. *Trends Biotechnol*. 2008; 26:201–209. [PubMed: 18295915]
- Lo IKY, Marchuk LL, Hollinshead R, Hart DA, Frank CB. Matrix Metalloproteinase and Tissue Inhibitor of Matrix Metalloproteinase mRNA Levels Are Specifically Altered in Torn Rotator Cuff Tendons. *The American Journal of Sports Medicine*. 2004; 32:1223–1229. [PubMed: 15262646]
- Lui PPY, Rui YF, Ni M, Chan KM. Tenogenic differentiation of stem cells for tendon repair-what is the current evidence? *Journal of Tissue Engineering and Regenerative Medicine*. 2011; 5:e144–e163. [PubMed: 21548133]
- Maeda E, Shelton JC, Bader DL, Lee DA. Differential regulation of gene expression in isolated tendon fascicles exposed to cyclic tensile strain in vitro. *J Appl Physiol*. 2009; 106:506–512. [PubMed: 19036888]
- O'Brien FJ, Harley BA, Waller MA, Yannas IV, Gibson LJ, Prendergast PJ. The effect of pore size on permeability and cell attachment in collagen scaffolds for tissue engineering. *Technol Health Care*. 2007; 15:3–17. [PubMed: 17264409]
- O'Brien FJ, Harley BA, Yannas IV, Gibson LJ. The effect of pore size on cell adhesion in collagen-GAG scaffolds. *Biomaterials*. 2005; 26:433–441. [PubMed: 15275817]
- O'Brien FJ, Harley BA, Yannas IV, Gibson L. Influence of freezing rate on pore structure in freeze-dried collagen-GAG scaffolds. *Biomaterials*. 2004; 25:1077–1086. [PubMed: 14615173]

- Olde Damink LHH, Dijkstra PJ, van Luyn MJA, van Wachem PB, Nieuwenhuis P, Feijen J. Cross-linking of dermal sheep collagen using a water-soluble carbodiimide. *Biomaterials*. 1996; 17:765–773. [PubMed: 8730960]
- Paxton JZ, Hagerty P, Andrick JJ, Baar K. Optimizing an Intermittent Stretch Paradigm Using ERK1/2 Phosphorylation Results in Increased Collagen Synthesis in Engineered Ligaments. *Tissue Eng Part A*. 2011
- Pelham RJ, Wang Y-l. Cell locomotion and focal adhesions are regulated by substrate flexibility. *Proceedings of the National Academy of Sciences*. 1997; 94:13661–13665.
- Peyton SR, Putnam AJ. Extracellular matrix rigidity governs smooth muscle cell motility in a biphasic fashion. *Journal of Cellular Physiology*. 2005; 204:198–209. [PubMed: 15669099]
- Pryce BA, Watson SS, Murchison ND, Staverosky JA, Dunker N, Schweitzer R. Recruitment and maintenance of tendon progenitors by TGFbeta signaling are essential for tendon formation. *Development*. 2009; 136:1351–1361. [PubMed: 19304887]
- Schulz Torres D, M Freyman T, Yannas IV, Spector M. Tendon cell contraction of collagen–GAG matrices in vitro: effect of cross-linking. *Biomaterials*. 2000; 21:1607–1619. [PubMed: 10885733]
- Schweitzer R, Zelzer E, Volk T. Connecting muscles to tendons: tendons and musculoskeletal development in flies and vertebrates. *Development*. 2010; 137:2807–2817. [PubMed: 20699295]
- Spilker MH, Asano K, Yannas IV, Spector M. Contraction of collagen–glycosaminoglycan matrices by peripheral nerve cells in vitro. *Biomaterials*. 2001; 22:1085–1093. [PubMed: 11352089]
- Taylor SE, Vaughan-Thomas A, Clements DN, Pinchbeck G, Macrory LC, Smith RK, Clegg PD. Gene expression markers of tendon fibroblasts in normal and diseased tissue compared to monolayer and three dimensional culture systems. *BMC Musculoskelet Disord*. 2009; 10:27. [PubMed: 19245707]
- Tierney CM, Jaasma MJ, O'Brien FJ. Osteoblast activity on collagen-GAG scaffolds is affected by collagen and GAG concentrations. *Journal of Biomedical Materials Research Part A*. 2009; 91A: 92–101.
- Towler DA, Gelberman RH. The alchemy of tendon repair: a primer for the (S)mad scientist. *J Clin Invest*. 2006; 116:863–866. [PubMed: 16585955]
- Vickers SM, Gotterbarm T, Spector M. Cross-linking affects cellular condensation and chondrogenesis in type II collagen-GAG scaffolds seeded with bone marrow-derived mesenchymal stem cells. *J Orthop Res*. 2010; 28:1184–1192. [PubMed: 20225321]
- Weisgerber DW, Kelkhoff DO, Caliarì SR, Harley BAC. The impact of discrete compartments of a multi-compartment collagen-GAG scaffold on overall construct biophysical properties. *J Mech Behav Biomed Mater*. 2013; 28:26–36. [PubMed: 23973610]
- Xu Y, Murrell GA. The basic science of tendinopathy. *Clin Orthop Relat Res*. 2008; 466:1528–1538. [PubMed: 18478310]
- Yannas, IV. *Tissue and organ regeneration in adults*. Springer; New York: 2001.
- Yannas IV, Lee E, Orgill DP, Skrabut EM, Murphy GF. Synthesis and characterization of a model extracellular matrix that induces partial regeneration of adult mammalian skin. *Proc Natl Acad Sci U S A*. 1989; 86:933–937. [PubMed: 2915988]
- Yeung T, Georges PC, Flanagan LA, Marg B, Ortiz M, Funaki M, Zahir N, Ming W, Weaver V, Janmey PA. Effects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion. *Cell Motility and the Cytoskeleton*. 2005; 60:24–34. [PubMed: 15573414]
- Zaman MH, Trapani LM, Sieminski AL, MacKellar D, Gong H, Kamm RD, Wells A, Lauffenburger DA, Matsudaira P. Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. *Proceedings of the National Academy of Sciences*. 2006; 103:10889–10894.

- Collagen scaffold anisotropy promotes maintenance of tenocyte phenotype
- Tenocyte phenotype preserved in scaffolds that resist cell-mediated contraction
- Pore size and crosslinking independently tune scaffold strut flexural rigidity
- Crosslinking more effectively reduces tenocyte contraction
- Increased contraction correlated with upregulated matrix remodeling




Figure 1. Tenocyte viability and contraction of CG scaffolds

(A) Metabolic activity of tenocytes at days 1 and 14 for all nine CG scaffold groups. (B) Normalized number of cells at day 14 for all nine CG scaffold groups (all scaffolds normalized vs. control scaffold with the largest pore size and highest crosslinking density). (C) Scaffold contraction, normalized to the initial scaffold diameter, at days 1, 4, 7, and 14 for all nine CG scaffold groups. Data expressed as mean \pm SEM ($n=6$). \vee : significantly ($p < 0.01$) lower than initial scaffold diameter. \dagger : significantly ($p < 0.01$) different than scaffolds of same pore size with lowest (1:1:5) crosslinking density. \ddagger : significantly ($p < 0.01$)

different than scaffolds of same pore size with middle (5:2:5) crosslinking density. *: significantly ($p < 0.01$) different from scaffolds of same crosslinking density with largest pore size ($-10^{\circ}\text{C } T_f$). #: significantly ($p < 0.01$) different from scaffolds of same crosslinking density with middle pore size ($-40^{\circ}\text{C } T_f$).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2. Structural protein gene expression

Expression levels of (A) *COL1A2*, (B) *COL3A1*, (C) *COMP*, and (D) *DCN* after 14 days in all 9 scaffold groups. Data expressed as mean \pm SEM (n=3). †: significantly ($p < 0.01$) different than scaffolds of same pore size with lowest (1:1:5) crosslinking density. ‡: significantly ($p < 0.01$) different than scaffolds of same pore size with middle (5:2:5) crosslinking density. *: significantly ($p < 0.01$) different from scaffolds of same crosslinking density with largest pore size (-10°C T_f). #: significantly ($p < 0.01$) different from scaffolds of same crosslinking density with middle pore size (-40°C T_f).




Figure 3. Tendon phenotype gene expression

Expression levels of (A) *SCX* and (B) *TNC* after 14 days in all 9 scaffold groups. Data expressed as mean \pm SEM (n=3). †: significantly ($p < 0.01$) different than scaffolds of same pore size with lowest (1:1:5) crosslinking density. ‡: significantly ($p < 0.01$) different than scaffolds of same pore size with middle (5:2:5) crosslinking density. *: significantly ($p < 0.01$) different from scaffolds of same crosslinking density with largest pore size ($-10^{\circ}\text{C } T_f$). #: significantly ($p < 0.01$) different from scaffolds of same crosslinking density with middle pore size ($-40^{\circ}\text{C } T_f$).




Figure 4. MMP gene expression

(A) MMP 1, (B) MMP3, and (C) MMP13 expression levels at days 1, 4, 7, and 14 relative to normalized scaffold diameter for all 9 scaffold groups. Data expressed as mean \pm SEM ($n=3$). The degree of correlation (R^2) was between gene expression and scaffold contraction was determined as a function of experimental time point (day 1, 4, 7, and 14).

Table 1

Effect of fabrication and crosslinking on scaffold structural and mechanical properties. This table summarizes previously reported data on pore size (Caliari and Harley, 2011) and the effect of crosslinking on elastic modulus (Harley et al., 2007b) and swelling ratio (Vickers et al., 2010).

T_b , °C	Transverse pore size, μm	EDC crosslinking	Relative stiffness, E/E_{DHT}
-10	242.7 ± 28.8	DHT (standard)	1.0 ± 0.051 ($E_{DHT} = 208 \pm 41$ Pa)
-40	152.4 ± 25.1	1:1:5	2.0 ± 0.11
-60	55.3 ± 17.6	5:2:1	7.20 ± 0.14

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2

PCR primer sequences.

Transcript	Sequence	Reference
<i>COL1A2</i>	Forward: 5'-GCACATGCCGTGACTTGAGA-3' Reverse: 5'-CATCCATAGTGCATCCTTGATTAGG-3'	(Taylor et al., 2009)
<i>COL3A1</i>	Forward: 5'-GTCCACCTGAGGAAGTGTCT-3' Reverse: 5'-TGATCAGGACCACCAACATCA-3'	(Taylor et al., 2009)
<i>COMP</i>	Forward: 5'-GGTGCGGCTGCTATGGAA-3' Reverse: 5'-CCAGCTCAGGGCCCTCAT-3'	(Taylor et al., 2009)
<i>DCN</i>	Forward: 5'-CATCCAGGTTGTCTACCTTCATAACA-3' Reverse: 5'-CCAGGTGGGCAGAAGTCATT-3'	(Taylor et al., 2009)
<i>SCX</i>	Forward: 5'-TCTGCCTCAGCAACCAGAGA-3' Reverse: 5'-TCCGAATCGCCGTCTTTC-3'	(Taylor et al., 2009)
<i>TNC</i>	Forward: 5'-GGGCGGCCTGGAAATG-3' Reverse: 5'-CAGGCTCTAACTCCTGGATGATG-3'	(Taylor et al., 2009)
<i>MMP1</i>	Forward: 5'-GGTGAAGGAAGGTCAAGTTCTGAT-3' Reverse: 5'-AGTCTTCTACTTTGGAAAAGAGCTTCT-3'	(Garvican et al., 2008)
<i>MMP3</i>	Forward: 5'-GCACATGCCGTGACTTGAGA-3' Reverse: 5'-CCTATGGAAGGTGACTCCATGTG-3'	(Garvican et al., 2008)
<i>MMP13</i>	Forward: 5'-CTGGAGCTGGGCACCTACTG-3' Reverse: 5'-ATTTGCCTGAGTCATTATGAACAAGAT-3'	(Garvican et al., 2008)
<i>GAPDH</i>	Forward: 5'-GCATCGTGGAGGGACTCA-3' Reverse: 5'-GCCACATCTTCCCAGAGG-3'	(Taylor et al., 2009)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript